en
svPress releases
Regulatory press release 2023-02-23
Xspray Pharma Partners with EVERSANA for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)
Regulatory press release 2023-02-15
Interim Report Fourth Quarter 2022
Press release 2022-12-13
Xspray presents novel scientific data for XS004 in the Chronic Myeloid Leukemia (CML) session at the 2022 Meeting of the American Society of Hematology
Press release 2022-11-30
Xspray Pharma’s drug candidate XS004 granted orphan drug designation in the US for the treatment of acute lymphoblastic leukemia
Regulatory press release 2022-11-09
Interim Report Third Quarter 2022
Press release 2022-11-03
Xspray Announces 2 Poster Presentations for XS004 in Chronic Myeloid Leukemia (CML) at the American Society of Hematology (ASH) 2022 Annual Meeting
Regulatory press release 2022-10-31
Number of shares and votes in Xspray Pharma
Regulatory press release 2022-10-25
Xspray Pharma’s Nomination Committee for the Annual General Meeting 2023
Regulatory press release 2022-10-17
Xspray Pharma has carried out a directed share issue raising proceeds of MSEK 100
Regulatory press release 2022-08-05